Atossa Genetics (ATOS) Expected to Announce Earnings on Tuesday

Atossa Genetics (NASDAQ:ATOS) is expected to be releasing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Atossa Genetics to post earnings of ($0.99) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 12:30 PM ET.

Atossa Genetics Price Performance

NASDAQ:ATOS traded down $0.38 during trading hours on Tuesday, hitting $5.48. The company’s stock had a trading volume of 164,520 shares, compared to its average volume of 118,398. The stock has a fifty day simple moving average of $5.09 and a 200-day simple moving average of $8.48. The company has a market capitalization of $47.15 million, a P/E ratio of -1.52 and a beta of 1.25. Atossa Genetics has a twelve month low of $3.76 and a twelve month high of $19.35.

Hedge Funds Weigh In On Atossa Genetics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in Atossa Genetics by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock valued at $810,000 after buying an additional 9,627 shares during the period. Hudson Bay Capital Management LP acquired a new position in Atossa Genetics in the second quarter valued at $26,000. JPMorgan Chase & Co. lifted its holdings in Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after buying an additional 35,474 shares during the period. Bank of America Corp DE lifted its stake in Atossa Genetics by 55.7% in the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after buying an additional 35,629 shares during the period. Finally, &PARTNERS acquired a new position in Atossa Genetics in the fourth quarter valued at approximately $25,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ATOS. HC Wainwright raised their target price on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a report on Monday, April 20th. Finally, Ascendiant Capital Markets cut their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, April 10th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Atossa Genetics presently has an average rating of “Hold” and a consensus target price of $36.33.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.